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Abstract 
 Although the extract of U.pilulifera has been used since a long time 
to treat diabetes, but its role in improving the situation of kidneys remains to 
be well established. The main objective of the present study is to investigate 
the effects of the extract of U. pilulifera on the expression of iNOS in 
kidneys of diabetic rats. Methodology of the present study included 
collection of U. pilulifera fromvarious places in Jordan, air dried and 
extracted by Soxhlet cold  extractor using absolute methanol as solvent and 
remained for three consecutive days. Extracted juice was kept in refrigerator 
at 4°C.  Diabetes was induced through administration of alloxan 150 mg/kg 
body weight intraperitoneally. Study model included 4 groups: control 
group, diabetic group, diabetic group treated with 1.25 mg/kg body weight, 
and diabetic group treated with 1.88 mg/kg body weight. Study findings 
showed increased significant expression of iNOS in diabetic group compared 
with control group (P 0.000). The extract of U.pilulifera significantly 
decreased the expression of iNOS in diabetic kidneys at both doses used, but 
more reduction of iNOS was observed using the large dose 1.88 mg/kg of 
body weight. Taken together, the present study confirmed the findings of 
other studies in which the expression of iNOS plays a role in diabetic kidney. 
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Therapeutic potential of U. pilulifera in treating diabetes has also been 
suggested to be mediated in diabetic kidneys through decreasing the 
expression of iNOS. 
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Introduction  
 Diabetic  nephropathy (DN) is considered as the most prevalent  
single cause of end-stage renal disease in the United States and Europe 
(Veelken et al., 2000). DN is characterized by being a long term 
complication with a prevalence about 30-40% of patients with diabetes 
mellitus (DM). It has been indicated that DN is associated with increased 
renal perfusion and glomerular filtration rate (GFR) (Bildirici et al., 2005).   
 According to Veelken et al (2000), it has been demonstrated through 
micropuncture studies that renal vasodilation is the cause of diabetic 
hyperfiltration. It was thought that renal vasodilatation to be due to increased 
production of nitric oxide (NO) (Craven et al., 1997). NO has several roles in 
vascular physiology, neurotransmission, inflammation and immune defense 
systems (Ignarro et al., 1987). Other studies showed that NO can act as a 
vascular and neural messenger through activating soluble guanylate cyclase 
which leads to elevated levels of cGMP. The origin of NO is L-arginine. The 
family of NOS proteins includes three main members neuronal NOS 
(nNOS), endothelial NOS (eNOS), and the inducible type (iNOS). iNOS has 
been found to be expressed by several cell types such as macro-phages, 
vascular smooth muscle cells, and glomerular mesangial cells, which cause 
the production of huge amounts of NO. Both of endotoxin and cytokines  can 
induce the production of No (Narita et al,. 1995).  
 According to a study of Sharma et al (1995), it has been postulated 
that diabetes can induce the production of  iNOS which, in turn, leads to 
increased generation of NO and by thus participates to diabetic 
hyperfiltration and glomerular abnormalities in diabetes. 
 Several studies have demonstrated that although diabetes is the main 
risk factor attributing for DN, but it is not responsible for  all observed 
changes in kidneys (Deckert and Poulsen, 1981; Krolewski et al., 1995; 
Kosugi et al., 2006). 
 In the kidney, nitric oxide regulates various physiological functions 
as glomerular capillary blood pressure, glomerular plasma flow and the 
glomerular ultrafiltration coefficient (Prabhakar, 2001). From a biological 
point of view, the effects of NO are due to the concentration of NO at the site 
of action and the specific location where NO is generated (Raij and Baylis, 
1995).  
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 It has been indicated that no exact role of iNOS is established in 
regulation of renal function as well as  its involvement in the pathogenesis of 
diabetic nephropathy is still a point of controversy (Shireen et al., 2009). 
Several studies have pointed to the expression of iNOS to be mainly in the 
tubules of normal kidneys (Ashab et al., 1995; Aiello et al., 1997). Other 
studies pointed to low or undetectable expression of iNOS in normal kidneys 
(Bank et al., 1996; Heeringa et al., 1998). On the other hand, studies that 
investigated the expression of iNOS in diabetes have shown conflicted 
outcomes. Some studies showed the expression of iNOS in diabetic rat 
kidney (Sugimoto et al., 1999; Cosenzi et al., 2002), while the expression of 
iNOS in diabetic kidney was not approved by another study (Veelken et al., 
2000). 
 In the present study, the effect of the extract of Urtica pilulifera (U. 
pilulifera) on the expression of inducible nitric oxide synthase (iNOS) on 
kidneys of diabetic rats was explored. Many studies in literature investigated 
both the effects of diabetes on the expression of iNOS as mentioned 
previously, and the effects of the extract of U.pilulifera on diabetes. Such 
studies have shown that the extracts of U.pilulifera have been used to treat 
various diseases including Diabetes Mellitus (Kavalali et al., 2003; Lopatkin 
et al., 2005).  
 
Study objectives 
 The main objective of the present study is to investigate the effects of 
the extract of U. pilulifera on the expression of iNOS in kidneys of diabetic 
rats. 
 
Study hypothesis 
 There is a significant relationship between the effects of the extracts 
of U.pilulifera and the expression of iNOS in kidneys of diabetic rats which 
may predict a new therapeutic approach to treat diabetic nephropathy.  
 
Methodology 
Plant collection and preparation of extraction  
 U. pilulifera leaves were collected from various areas at Jordan, air-
dried in shad well-ventilated area and then ground into fine powder.  About 
350 g of powder was put in a Soxhlet cold  extractor using absolute methanol 
as solvent and remained for three consecutive days (Sadki et al., 2001). The 
extract was concentrated to dryness in rotary evaporator under reduced 
pressure and controlled temperature (45°C) to yield an 11.4% viscous 
greenish-colored extract. The extract was kept at 4°C in a glass container 
until use. Wister rats were used in this study, in which their average weight 
was 170 g. The conditions in animal house were to place rats in stainless 
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steel cages under  12 h light/dark cycle throughout the experimental periods. 
They had access to food (top fed, Sapele) and water ad libitum. The animals 
were carefully checked and monitored every day for any changes. After 
determination of  lethal dose (LD50), two doses were selected 1.25 g/kg and 
1.88 g/kg of body weight. Doses were prepared through dissolving required 
amount of the viscous extract in 10 mL Tween-20: 0.9% NaCl (1:9, V/V).  
 
Diabetic model 
 Diabetes was induced depending on alloxan so that rats were injected 
by alloxan monohydrate "B.O.H chemical LTD England" intraperitoneally  
at a dose of 150 ml/kg body weight (dissolved in fresh normal saline) to 18 
hr fasted rat. Rats were monitored for blood glucose and rats with blood 
glucose level over 200 mg/ml, were considered diabetic and employed in the 
study. 
 Animals were assigned into the following groups:  
 Group I: control group; Group II: diabetic group; Group III: diabetic 
treated with 1.25 mg/kg of body weight; Group IV: diabetic treated with 1.88 
mg/kg of body weight. 
 
Immunohistochemistry 
 Immunohistochemical detection of iNOS was performed using 
commercially available mouse monoclonal antibodies. Immunohistochemical 
detections of iNOS was demonstrated by using labeled streptavidin biotin 
LSAB kit, which consists of secondary biotinylated goat anti-mouse 
antibody and conjugated streptavidin. Horse raddish peroxidase was 
followed by 3',3'-Diaminobenzidine (DAB) chromogen. Sections were 
processed for immunohistochemistry using conventional techniques (Khatib, 
2013).  
 
Immunohistochemical Assessment of Stained Sections  
 Slides were assessed using adopy photoshop software. Photos for 
sections were taken and divided into pixels. The total number of pixels was 
computed and represented both colours (blue and brown), then the brown 
colour (the colour of the marker under study) was computed and divided by 
the total number of pixels  (  Khatib, 2013).  
 
Statistical Analysis  
 The expression of HSP70 was compared between groups using T test.  
P value < 0.05 was considered statistically significant.  
 
Study findings  
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 After the end of the experiment, the expression of iNOS in kidneys of 
control group was 0.54. Among diabetic group, the expression of iNOS 
increased significantly (P 0.000) in kidneys of diabetic rat to 0.79. The effect 
of the extract of U. pilulifera was investigated through two doses, 1.25 
mg/kg of body weight and 1.88 mg/kg of body weight. Comparing diabetic 
group and diabetic group treated with 1.25 mg/kg of body weight, the results 
revealed significant decreased expression of iNOS in kidneys of diabetic rats 
from 0.79 to 0.63 respectively (P 0.000). Further significant decreased 
expression of iNOS (0.51, P 0.000) was noted in kidneys of diabetic rats 
treated with 1.88 mg/kg of body weight (Figure 1).  
 
Figure 1: Expression of iNOS among study groups 
 
Discussion 
 The present study investigated the effects of the extract U. pilulifera 
on the expression of iNOS on kidneys of diabetic rats. The results of the 
present study showed significant increased expression of iNOS in the 
kidneys of diabetic rats compared with control study. Our findings confirm 
other studies such as that of Sharma et al (1995), Sugimoto et al (1999) and 
Cosenzi et al (2002) in which it has been postulated that diabetes can induce 
the production of  iNOS which, in turn, leads to increased generation of NO 
and by thus participates to diabetic hyperfiltration and glomerular 
abnormalities in diabetes. However, our results do not agree with other 
studies in which iNOS has been indicated not to have exact role in regulation 
of renal function as well as  its involvement in the pathogenesis of diabetic 
nephropathy is still a point of controversy (Shireen et al., 2009). We also do 
not agree with other researchers who reported low or undetectable expression 
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of iNOS in normal kidneys (Bank et al., 1996; Heeringa et al., 1998). We 
also do not agree with the results of Veelken et al (2000) who did not 
approve the expression of iNOS in diabetic kidney. 
 It is worth to mention that technical issues may be beyond the 
detection of iNOS in kidneys and improvements of immunohitochemistry 
have helped greatly in localization of tissue antigens. 
 The results of our study showed a significant decreased expression of 
iNOS in diabetic kidney using either 1.25 mg/kg of body weight or 1.88 
mg/kg of body weight. Profound effects were seen using the large dose. 
These findings agree with other results which showed significant effects of 
U. pilulifera on diabetic persons (Kavalali et al., 2003; Lopatkin et al., 2005). 
These studies did not show how molecular mechanisms are involved in 
improving diabetic conditions. The importance of the present studies comes 
through opening new doors for understanding the effects of herbal 
treatments. 
 
Conclusion 
 The present study confirmed the findings of other studies in which 
the expression of iNOS plays a role in diabetic kidney. Therapeutic potential 
of U. pilulifera in treating diabetes has also been suggested to be mediated in 
diabetic kidneys through decreasing the expression of iNOS. 
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